Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

799.84 -3.33 (-0.41%)
Streaming Delayed Price Updated: 1:36 PM EDT, May 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 838,005
Open 801.00
Bid (Size) 799.85 (4)
Ask (Size) 800.39 (2)
Prev. Close 803.17
Today's Range 795.25 - 802.30
52wk Range 434.34 - 816.61
Shares Outstanding N/A
Dividend Yield 0.57%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Australia Bans Replica Versions Of Popular Weight-Loss Drugs From Novo Nordisk, Eli Lilly On Safety Concerns
Compounding weight loss drugs, which are similar to brand-name medications such as Ozempic and Mounjaro, will be banned in Australia. 
Via Benzinga
The 500 Top Stocks to Buy in May, According to AI
MarketMaster AI tells us that the top stocks to buy in May represent high-quality companies with strong fundamentals. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence

Performance

YTD
+35.06%
+35.06%
1 Month
+9.37%
+9.37%
3 Month
+5.85%
+5.85%
6 Month
+34.97%
+34.97%
1 Year
+76.20%
+76.20%

More News

Read More
Retire Rich: 3 Game-Changing Stocks to Own for the Next 10 Years
Via InvestorPlace
Topics Retirement
Exposures Pension
This Biotech Stock Is Poised For 80% Upside With Breakthrough In Obesity Drug Market, Says JPMorgan
Via Benzinga
Tesla's Fall From Grace: Down 55% From Its Peak
Via Talk Markets
Here's How Much $100 Invested In Eli Lilly and Co 5 Years Ago Would Be Worth Today
Via Benzinga
Evaluating Eli Lilly and Co Against Peers In Pharmaceuticals Industry
Via Benzinga
EXCLUSIVE: Roundhill Investments Launches Weight Loss ETF For Exposure To Blockbuster Drugs Like Ozempic
Via Benzinga
Topics ETFs
3 Growth Stocks That Could Be Millionaire-Makers: May Edition
Via InvestorPlace
Weight Loss Drugs Like Wegvoy and Zepbound Users - Nestlé Launches $5 Pizza For You
Via Benzinga
If You'd Invested $10,000 in Eli Lilly Stock 5 Years Ago, Here's How Much You'd Have Today
Via The Motley Fool
7 Reliable Blue-Chip Stocks That Cannot Miss
Via InvestorPlace
Eli Lilly Secures China Nod For Popular Weight Loss/Diabetes Drug Tirzepatide
Via Benzinga
3 S&P 500 Stocks to Buy in May Before They Rocket Higher
Via InvestorPlace
Topics Stocks
Exposures US Equities
HIMS Stock Alert: Hims & Hers Shares Rocket on Weight Loss Injections
Via InvestorPlace
Magnificent Seven? Just Two Members Meet This Earnings Criteria
Via Investor's Business Daily
Is Amgen a Threat to Eli Lilly in This Billion-Dollar Market?
Via The Motley Fool
EXCLUSIVE: GameStop, AMC Buzz 'May Prove To Be Short-Lived,' CEO Of Company Behind MEME ETF Tells Benzinga
Via Benzinga
Topics ETFs
Pharma Stocks Outlook: Where Are 2024’s Top Performers Headed Next?
Via InvestorPlace
Rally Rockets: 3 Stocks Benefitting From the Market’s Unstoppable Surge
Via InvestorPlace
Elevai Labs (NASDAQ: ELAB) Acquires Rights To Develop Muscle Loss Prevention Assets For Anticipated Use In Anti-Obesity Treatments, Launches Two New Subsidiaries
Via News Direct
Meet the GLP-1 Drug That Could Be the Biggest Concern for Eli Lilly and Novo Nordisk
Via The Motley Fool
3 Stocks To Buy Following Positive Earnings Results
Via Talk Markets
Topics Stocks
Exposures US Equities
Eli Lilly's Weekly Insulin Dose On Par With Commonly Used Daily Doses, Phase 3 Studies Show
Via Benzinga
The Dividend Investor’s Playbook: 3 Stocks for Consistent Cash Flow in 2024
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.